Get the Stockscreener App
9.36
0.65%
0.06
After Hours:
9.25
-0.11
-1.18%
Regenxbio Inc stock is traded at $9.36, with a volume of 651.84K.
It is up +0.65% in the last 24 hours and up +9.22% over the past month.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
See More
Previous Close:
$9.30
Open:
$9.29
24h Volume:
651.84K
Relative Volume:
0.70
Market Cap:
$483.10M
Revenue:
$170.44M
Net Income/Loss:
$-193.88M
P/E Ratio:
-2.4933
EPS:
-3.7541
Net Cash Flow:
$-126.38M
1W Performance:
+7.96%
1M Performance:
+9.22%
6M Performance:
-23.90%
1Y Performance:
+42.90%
1-Day Range:
$9.26
$9.60
1-Week Range:
$8.41
$9.60
52-Week Range:
$5.85
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
9.36 | 480.00M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
Lifshitz Law Firm Investigating PayPal, Enphase Energy, and REGENXBIO - National Today
RGNX DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts REGENXBIO Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
REGENXBIO Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
REGENXBIO (RGNX) 2026 proxy details director votes, auditor, and stock option exchanges - Stock Titan
RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REG - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX - GlobeNewswire Inc.
RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Bluefield Daily Telegraph
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026 - 巴士的報
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - GlobeNewswire
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGE - GuruFocus
REGENXBIO DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class ActionRGNX - ACCESS Newswire
Levi & Korsinsky, LLP: RGNX Disclosure Timeline Reveals Pattern of Alleged Investor Harm - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Rosen Law Firm Encourages REGENXBIO Investors to Secure Counsel Before Deadline - National Today
REGENXBIO DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages REGENXBIO, Inc. Investors with ... - Bluefield Daily Telegraph
REGENXBIO DEADLINE: ROSEN, A LEADING AND RANKED FIRM, - GlobeNewswire
How (RGNX) Movements Inform Risk Allocation Models - Stock Traders Daily
Portfolio Shifts: How is REGENXBIO Inc managing supply chain issues2026 Sentiment & High Conviction Investment Ideas - baoquankhu1.vn
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO ... - Bluefield Daily Telegraph
RGNX Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - PR Newswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRGNX - wahanariau.com
Press releases provided by CNW - Techaeris
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - GuruFocus
Institution Moves: Is REGENXBIO Inc stock showing strong momentumOil Prices & Safe Entry Zone Identification - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming DeadlinesRGNX - PR Newswire
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of REGENXBIO Inc. to Contact the Firm Today! - ACCESS Newswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
RGNX Stockholders Have Opportunity to Lead REGENXBIO Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX - FinancialContent
RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline i - GuruFocus
RGNX Shareholders Have Opportunity to Lead REGENXBIO Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline in REGENXBIO Inc. Securities Class Action Lawsuit -- The Gross Law Firm - Barchart.com
RGNX Technical Analysis | Trend, Signals & Chart Patterns | REGENXBIO INC (NASDAQ:RGNX) - ChartMill
Book value per share of REGENXBIO, Inc. – SWB:RB0 - TradingView — Track All Markets
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securitie - GuruFocus
Metachromatic Leukodystrophy Treatment Market to Reach US$ - openPR.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
CapEx per share of REGENXBIO, Inc. – SWB:RB0 - TradingView
Tangible book value per share of REGENXBIO, Inc. – SWB:RB0 - TradingView
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. - GlobeNewswire
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
RGNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO ( - GuruFocus
RGNX PE Ratio & Valuation, Is RGNX Overvalued - Intellectia AI
RGNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - ChartMill
REGENXBIO, Inc. Class Action ReminderRobbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights - Sahm
REGENXBIO: CEO Makes Major Sale During Legal Battle While Investors Split - Bitget
REGENXBIO (RGNX) proxy: directors, PwC ratification, option-exchange votes - Stock Titan
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):